A Study to Evaluate Brenipatide Compared with Placebo in Adult Participants with Uncontrolled Moderate to Severe Asthma
Key facts
- Where
- Aix En Provence, Brest, Cholet, Le Chesnay Cedex, Le Kremlin-Bicetre, Montfermeil, Paris Cedex 18, Pessac, Rennes és Suresnes, FranciaországSee the 10 sites
- Phase
- 2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Franciaország
- Centre Hospitalier Du Pays D Aix Centre Hospitalier Intercommunal Aix-PertuisAix En Provence, FranciaországTaking people
- Centre Hospitalier Régional et Universitaire de BrestBrest, FranciaországTaking people
- Centre Hospitalier de CholetCholet, FranciaországTaking people
- Centre Hospitalier De VersaillesLe Chesnay Cedex, FranciaországTaking people
- Assistance Publique Hopitaux De ParisLe Kremlin-Bicetre, FranciaországTaking people
- Groupe Hospitalier Intercommunal Le Raincy MontfermeilMontfermeil, FranciaországTaking people
- Assistance Publique Hopitaux De ParisParis Cedex 18, FranciaországTaking people
- Centre Hospitalier Universitaire de BordeauxPessac, FranciaországTaking people
- Centre Hospitalier Universitaire de RennesRennes, FranciaországTaking people
- Hospital FochSuresnes, FranciaországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly & Co.
- Trial code
- EU 2025-522640-41-00
- Record updated
- 2026. augusztus 26.
- Original description
To evaluate the efficacy of brenipatide relative to placebo in reducing severe asthma exacerbationsRead full original descriptionShow less
J2S-MC-GZMR: A Phase 2, Multicenter, Randomized, Double-blind, 52-week Study, to Investigate the Efficacy and Safety of Brenipatide Compared with Placebo for the Treatment of Adult Participants with Uncontrolled Moderate to Severe Asthma
To evaluate the efficacy of brenipatide relative to placebo in reducing severe asthma exacerbations
Inclusion: Participants must have been diagnosed with asthma and have received an asthma controller medication prescribed by their doctor for at least 12 months prior to screening; Participants must have a history of 1 severe asthma exacerbation that led to oral steroid treatment in the last 12 months prior to screening.
Exclusion: Participants must not have a Lung condition other than asthma, such as smoker’s lung, infections that has been going on for a long time or didn’t go away completely; Participants must not have a Diagnosis of job-related asthma.